|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder | |||||||||||
| 化学式 | C18H15Cl2N3O3 |
||||||||||||||
| 分子量 | 392.24 | CAS No. | 2243736-45-8 | ||||||||||||
| Solubility (25°C)* | 体外 | DMSO (warmed with 50ºC water bath) | 78 mg/mL (198.85 mM) | ||||||||||||
| Water | Insoluble | ||||||||||||||
| Ethanol | Insoluble | ||||||||||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||||||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||||||||||
| 製品説明 | FB23-2 is a potent and selective FTO inhibitor that directly binds to FTO and selectively inhibits FTO's N6-methyladenosine (m6A) demethylase activity with IC50 of 2.6 μM. |
|---|---|
| in vitro | FB23-2 directly binds to FTO and selectively inhibits its m6A demethylase activity. Mimicking FTO depletion, this compound dramatically suppresses proliferation and promotes the differentiation/apoptosis of human acute myeloid leukemia (AML) cell line cells and primary blast AML cells in vitro.[1] |
| in vivo | FB23-2 significantly inhibits the progression of human AML cell lines and primary cells in xeno-transplanted mice.[1] |
| 細胞アッセイ | 細胞株 | Leukemia cells NB4, U937, MV4-11, ML-2; MONOMAC6 (ACC-124) cells; 293T cells; The mouse bone marrow cells FLT3ITD/NPM1, MA9 |
|---|---|---|
| 濃度 | 10 μM, 5 μM | |
| 反応時間 | 24 h, 72 h | |
| 実験の流れ | NB4 and MONOMAC6 cells are treated with DMSO or FB23-2 at varying concentrations for 72 h, while MA9 and FLT3/NPM1 primary cells isolated from AML mice, five human AML cell (MA9.3ITD, MA9.3RAS, U937, ML2, and MV4-11), and human primary AML cells are treated with DMSO or 5 μM of this compound for 72 h for dot blot assay. |
|
| 動物実験 | 動物モデル | NSGS mice with xeno-transplantation model |
| 投薬量 | 2 mg/kg | |
| 投与方法 | IP |
|
| FTO suppresses DNA repair by inhibiting PARP1 [ Nat Commun, 2025, 16(1):2925] | PubMed: 40133293 |
| Hypoxia-induced degradation of FTO promotes apoptosis by unmasking RACK1-mediated activation of MTK1-JNK1/2 pathway [ J Adv Res, 2025, S2090-1232(25)00038-4] | PubMed: 39805423 |
| RNA N6-methyladenosine demethylase FTO promotes diabetic wound healing through TRIB3-mediated autophagy in an m6A-YTHDF2-dependent manner [ Cell Death Dis, 2025, 16(1):222] | PubMed: 40157922 |
| NRF2 maintains redox balance via ME1 and NRF2 inhibitor synergizes with venetoclax in NPM1-mutated acute myeloid leukemia [ Cancer Metab, 2025, 13(1):32] | PubMed: 40533864 |
| YTHDF2 upregulation and subcellular localization dictate CD8 T cell polyfunctionality in anti-tumor immunity [ Nat Commun, 2024, 15(1):9559] | PubMed: 39500904 |
| m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway [ J Exp Clin Cancer Res, 2023, 42(1):217] | PubMed: 37605223 |
| Targeting AKT induced Ferroptosis through FTO/YTHDF2-dependent GPX4 m6A methylation up-regulating and degradating in colorectal cancer [ Cell Death Discov, 2023, 9(1):457] | PubMed: 38102129 |
| Cytoplasmic Expression of TP53INP2 Modulated by Demethylase FTO and Mutant NPM1 Promotes Autophagy in Leukemia Cells [ Int J Mol Sci, 2023, 24(2)1624] | PubMed: 36675134 |
| m6A demethylase FTO renders radioresistance of nasopharyngeal carcinoma via promoting OTUB1-mediated anti-ferroptosis [ Transl Oncol, 2023, 27:101576] | PubMed: 36343416 |
| E6E7 regulates the HK2 expression in cervical cancer via GSK3β/FTO signal [ Arch Biochem Biophys, 2022, 729:109389] | PubMed: 36075458 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。